TibaRay, a Stanford spinout developing next-generation accelerator technology for FLASH radiotherapy, has launched a Regulation CF campaign on Wefunder, opening the company to individual investors. The campaign aims to raise capital as TibaRay continues to advance its Galactica linear accelerator and work toward the deployment of its PHASER radiotherapy system, designed to deliver radiation hundreds of times faster than current systems.
FLASH radiotherapy is an emerging treatment modality that delivers radiation at ultra-high dose rates, potentially reducing damage to healthy tissue while maintaining tumor control. Research in recent years has suggested that this approach could transform cancer treatment, but it requires fundamentally new accelerator technology. TibaRay is developing that technology, leveraging decades of research in accelerator physics and medical physics.
To date, more than $27 million has been invested in TibaRay’s technology, including over $14 million in non-dilutive federal research grants. The company’s intellectual property portfolio includes more than 20 issued and pending patents related to next-generation radiotherapy systems. TibaRay’s proprietary Galactica linear accelerator has already been designed into Leo Cancer Care’s upright radiotherapy system, marking the company’s first commercial integration of its accelerator platform.
TibaRay is pursuing a phased commercialization strategy. In the near term, the company generates revenue by commercializing its accelerator technology across medical and adjacent markets, including imaging, security scanning, and non-destructive testing. The long-term objective is the deployment of the PHASER radiotherapy system, which is designed to enable ultrafast treatment delivery.
The Wefunder campaign allows individual investors to participate in this next phase of development. Investors can review the full opportunity, including technology details, partnerships, and development plans on the TibaRay campaign page.
The launch of this campaign underscores the growing interest in FLASH radiotherapy and the potential for new accelerator technologies to revolutionize cancer care. By enabling individual investors to contribute, TibaRay is broadening the base of support for its mission to cure cancer in a FLASH.
